{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:25Z","timestamp":1791489625908,"version":"4.3.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":244,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008108","name":"Taipei Tzu Chi Hospital","doi-asserted-by":"publisher","award":["TCRD-TPE-113-14"],"award-info":[{"award-number":["TCRD-TPE-113-14"]}],"id":[{"id":"10.13039\/501100008108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008108","name":"Taipei Tzu Chi Hospital","doi-asserted-by":"publisher","award":["TCRD-TPE-115-65"],"award-info":[{"award-number":["TCRD-TPE-115-65"]}],"id":[{"id":"10.13039\/501100008108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101422","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:22:27Z","timestamp":1789204947000},"page":"101422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical application of serum Mac-2-binding protein glycosylation isomer in the diagnosis of liver fibrosis: a meta-analysis"],"prefix":"10.1016","volume":"49","author":[{"given":"Jiann-Hwa","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-8141","authenticated-orcid":false,"given":"I-Shiang","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101422_bib0001","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jhep.2020.03.011","article-title":"Hepatic fibrosis: a convergent response to liver injury that is reversible","volume":"73","author":"Wang","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ctarc.2026.101422_bib0002","article-title":"Noninvasive tests for liver fibrosis in 2024: are there different scales for different diseases?","volume":"12","author":"Lai","year":"2024","journal-title":"Gastroenterol. Rep. (Oxf.)"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101422_bib0003","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.11.050","article-title":"Refining the baveno VI elastography criteria for the definition of compensated advanced chronic liver disease","volume":"74","author":"Papatheodoridi","year":"2021","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101422_bib0004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ctarc.2026.101422_bib0005","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.2147\/IDR.S402990","article-title":"FibroScan predicts liver fibrosis progression in chronic HBV infection patients with no clear indication for antiviral therapy: a retrospective cohort study","volume":"Volume 16","author":"Xu","year":"2023","journal-title":"Infect. Drug Resist."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101422_bib0006","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00535-017-1425-z","article-title":"Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis","volume":"53","author":"Shirabe","year":"2018","journal-title":"J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101422_bib0007","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3350\/cmh.2020.0032","article-title":"Novel biomarkers for the management of chronic hepatitis B","volume":"26","author":"Inoue","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101422_bib0008","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1007\/s10620-023-08143-5","article-title":"Evaluating M2BPGi as a marker for liver fibrosis in patients with chronic hepatitis B","volume":"68","author":"Bui","year":"2023","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101422_bib0009","article-title":"Intraindividual changes in Mac-2 binding protein glycosylation isomer (M2BPGi) performed in Korean subjects","volume":"68","author":"Choi","year":"2022","journal-title":"Clin. Lab."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101422_bib0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/jgh.13834","article-title":"A noninvasive diagnosis of hepatic fibrosis by BioFibroScore\u00ae in chronic hepatitis C patients","volume":"33","author":"Liu","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101422_bib0011","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3343\/alm.2021.41.3.302","article-title":"Diagnostic efficacy of serum Mac-2 binding protein glycosylation isomer and other markers for liver fibrosis in non-alcoholic fatty liver diseases","volume":"41","author":"Jang","year":"2021","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.ctarc.2026.101422_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1382293","article-title":"The value of serum Mac-2 binding protein glycosylation isomer in the diagnosis of liver fibrosis: a systematic review and meta-analysis","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ctarc.2026.101422_bib0013","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.17611","article-title":"Evaluation of Mac-2 binding protein glycosylation isomer (M2BPGi) as a diagnostic marker for staging liver fibrosis: a meta-analysis","volume":"12","author":"Gong","year":"2024","journal-title":"PeerJ."},{"key":"10.1016\/j.ctarc.2026.101422_bib0014","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/apt.13431","article-title":"Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy ofdirect-acting anti-viral-based triple therapy for chronic hepatitis C","volume":"43","author":"Ura","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ctarc.2026.101422_bib0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.kjms.2017.05.017","article-title":"Serum wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients","volume":"33","author":"Huang","year":"2017","journal-title":"Kaohsiung. J. Med. Sci."},{"key":"10.1016\/j.ctarc.2026.101422_bib0016","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/jcm7090267","article-title":"Fibrosis staging using direct serum biomarkers is influenced by hepatitis activity grading in hepatitis C virus infection","volume":"7","author":"Fujita","year":"2018","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ctarc.2026.101422_bib0017","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hepr.12703","article-title":"Clinical implications of serum wisteria floribunda agglutinin-positive mac-2-binding protein in treatment-naive chronic hepatitis B","volume":"47","author":"Ishii","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ctarc.2026.101422_bib0018","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/hepr.12712","article-title":"Serum wisteria floribunda agglutinin-positive human Mac-2 binding protein may predict liver fibrosis and progression to hepatocellular carcinoma in patients with chronic hepatitis B virus infection","volume":"47","author":"Ichikawa","year":"2017","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ctarc.2026.101422_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220663","article-title":"Wisteria floribunda agglutinin-positive mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients","volume":"14","author":"Yeh","year":"2019","journal-title":"PLoS. One"},{"key":"10.1016\/j.ctarc.2026.101422_bib0020","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3343\/alm.2018.38.4.348","article-title":"Diagnosis of liver fibrosis with wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP) among chronic hepatitis B patients","volume":"38","author":"Jekarl","year":"2018","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.ctarc.2026.101422_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/s41424-018-0020-9","article-title":"Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection","volume":"9","author":"Mak","year":"2018","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.ctarc.2026.101422_bib0022","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00535-014-1007-2","article-title":"Association between wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease","volume":"50","author":"Abe","year":"2015","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.ctarc.2026.101422_bib0023","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/jgh.14156","article-title":"Wisteria floribunda agglutinin-positive mac-2-binding protein and type 4 collagen 7S: useful markers for the diagnosis of significant fibrosis in patients with non-alcoholic fatty liver disease","volume":"33","author":"Ogawa","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ctarc.2026.101422_bib0024","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1111\/hepr.12662","article-title":"Clinical significance of serum wisteria floribunda agglutinin positive mac-2-binding protein level in non-alcoholic steatohepatitis","volume":"46","author":"Nishikawa","year":"2016","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ctarc.2026.101422_bib0025","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/hepr.13046","article-title":"Serum wisteria floribunda agglutinin-positive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein","volume":"48","author":"Atsukawa","year":"2018","journal-title":"Hepatol. Res."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101422_bib0026","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/kjm2.12474","article-title":"Serum wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients","volume":"38","author":"Jang","year":"2022","journal-title":"Kaohsiung. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101422_bib0027","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1038\/s41598-020-62631-6","article-title":"Prognostic role of serum wisteria floribunda agglutinin-positive mac-2 binding protein level in early stage hepatocellular carcinoma","volume":"10","author":"Lin","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101422_bib0028","article-title":"Serum levels of M2BPGi as short-term predictors of hepatocellular carcinoma in untreated chronic hepatitis B patients","volume":"7","author":"Liu","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101422_bib0029","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-74466-2","article-title":"Early identification using the referral system prolonged the time to onset for hepatic encephalopathy after diagnosing severe acute liver injury","volume":"10","author":"Kakisaka","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101422_bib0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.20842","article-title":"Histopathology of pediatric nonalcoholic fatty liver disease","volume":"42","author":"Schwimmer","year":"2005","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101422_bib0031","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/j.gastro.2016.03.009","article-title":"Schwimmer JB. comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease","volume":"150","author":"Nobili","year":"2016","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101422_bib0032","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep4.1321","article-title":"Mac-2 binding protein glycosylation isomer as a hepatocellular carcinoma marker in patients with chronic hepatitis B or C infection","volume":"3","author":"Jun","year":"2019","journal-title":"Hepatol. Commun."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101422_bib0033","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00535-017-1425-z","article-title":"Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis","volume":"53","author":"Shirabe","year":"2018","journal-title":"J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101422_bib0034","doi-asserted-by":"crossref","first-page":"138","DOI":"10.17085\/apm.21038","article-title":"Trial sequential analysis: novel approach for meta-analysis","volume":"16","author":"Kang","year":"2021","journal-title":"Anesth. Pain. Med. (Seoul)"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:40:33Z","timestamp":1791488433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":34,"alternative-id":["S2468294226003321"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101422","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical application of serum Mac-2-binding protein glycosylation isomer in the diagnosis of liver fibrosis: a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101422"}}